<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186095</url>
  </required_header>
  <id_info>
    <org_study_id>BMT129</org_study_id>
    <nct_id>NCT00186095</nct_id>
  </id_info>
  <brief_title>Mixed Chimeric Transplantation for Primary Amyloidosis</brief_title>
  <official_title>Mixed Chimeric Transplantation for Primary Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Closed, never started.
  </why_stopped>
  <start_date>December 2000</start_date>
  <completion_date>September 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in marrow and serum abnormalities</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in end-organ function.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Amyloidosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous followed by nonmyeloablative allogeneic transplant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary amyloidosis

          -  adequate organ function

          -  matched sibling donor

        Exclusion Criteria:

          -  evidence of multiple myeloma

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Stockerl-Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>October 5, 2007</last_update_submitted>
  <last_update_submitted_qc>October 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2007</last_update_posted>
  <keyword>Amyloidosis</keyword>
  <keyword>nonmyeloablative</keyword>
  <keyword>hematopoietic</keyword>
  <keyword>cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

